Caregen, a biotechnology company (CEO Yongji Jeong), successfully concluded the 'Dubai Derma 2025' exhibition held at the Dubai World Trade Center from the 14th to the 16th.
'Dubai Derma' is the largest skin care exhibition in the MENA (Middle East and North Africa) region. This year, it was held on the largest scale ever, with over 25,000 buyers from 114 countries participating.
At this event, the Caregen booth was packed with overseas buyers from various countries. At the exhibition, Caregen focused on introducing its core technology-based 'Dr. CYJ Hair Filler' and new inner beauty product 'Korglutide'.
'DR. CYJ Hair Filler' is the world's first peptide-based injectable scalp care product. It is a highly functional product that improves scalp blood flow and promotes hair follicle regeneration to prevent hair loss and promote hair growth. It contains 7 types of bio-peptides and hyaluronic acid, and is a combination of ingredients with enhanced growth factor induction functions, ensuring both safety and effectiveness. It is administered using mesotherapy, which is directly injected into the scalp. Since it is possible to return to daily life immediately after the procedure without a separate recovery period, it is widely used in the male and female beauty medical markets, and it is a representative product that has been consistently exported overseas for many years. In particular, the Middle East is a region where the male hair loss rate reaches 60%, and due to cultural characteristics, there is a high level of resistance to existing hormone-suppressing hair loss treatments, so Caregen's non-hormonal products are demonstrating differentiated competitiveness.
Caregen has a diverse lineup of hair care products, including hair fillers, 'Dr. CYJ iDR' for damaged hair restoration, and topical products for hair loss. The solid lineup, built on long-term accumulated research experience, is sufficient to meet the diverse needs of the MENA market.
Meanwhile, the inner beauty product 'Korglutide' also received a hot response at this exhibition. 'Korglutide' is a peptide-based inner beauty product for body shape improvement and healthy weight management, and its strength is its safety with almost no side effects. It is based on the same mechanism as GLP-1 receptor agonists such as Wegovy and Ozempic, but it is released as a health functional food (food supplement) rather than a drug form, providing a more convenient and everyday solution to female consumers who pursue beauty and maintaining a beautiful body shape. It is attracting attention as an alternative that can simultaneously increase accessibility and acceptance in the Middle East, where psychological resistance to drug treatment is high.
Caregen is currently accelerating the registration process for 'Korglutide' in each Middle Eastern country and is concretizing its registration and distribution strategy through collaboration with exclusive partners in each country.
The overall hair care market in the MENA region is expected to grow to approximately KRW 9 trillion (approximately USD 6.75 billion) by 2029. The inner beauty and body management market is also classified as a high-growth industry, and the demand for premium healthcare products is particularly increasing.
A Caregen official said, “Through this exhibition, we were able to solidify our brand awareness and technological prowess in the global market,” adding, “We were able to increase our market share and further solidify our foundation for growth with our scientific and safe solutions for obesity and hair loss.”
Caregen plans to continue to strengthen its competitiveness in the global aesthetic medicine market based on peptide-based bio innovation.
- See more related articles
You must be logged in to post a comment.